Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Current Medicinal Chemistry
Title: TRAIL: A Sword for Killing Tumors
Volume: 17 Issue: 29
Author(s): S. Wang
Affiliation:
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Export Options
About this article
Cite this article as:
Wang S., TRAIL: A Sword for Killing Tumors, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176285
DOI https://dx.doi.org/10.2174/092986710793176285 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Identification of Novel Potent Inhibitors Against Bcl-xL Anti-apoptotic Protein Using Docking Studies
Protein & Peptide Letters HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics Pre-therapy Iodine-131 Uptake Value as a Prediction Method for Metastatic Lymph Node Status in Patients with Differentiated Thyroid Carcinoma
Current Medical Imaging Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Patents in Cancer Stem Cells
Recent Patents on Biomarkers The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design Prognostic Value of MiRNAs in Patients with Laryngeal Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets